Readers Insight
Publisher of open access books and journals

PJMLS OPEN ACCESS

Print ISSN: 2707-4471. Online ISSN: 2707-448X

Review Article	Pak-Euro Journal of Medical and Life Sciences
DOI: 10.31580/23r3ey14	Copyright © All rights are reserved by Corresponding Author
Vol. 8 No. 3, 2025: pp. 609-620	
www.readersinsight.net/pjmls	**Revised:** September 25, 2025 **Accepted:** September 28, 2025
Submission: July 11, 2025	**Published Online:** September 30, 2025

AI-DRIVEN PERSONALIZED CANCER TREATMENT: INTEGRATING GENOMIC DATA FOR TARGETED THERAPY DECISIONS

Rawia Sheikh[1], Carita Johnsan Dean[1], Muhammad Akhlaq[2], Shahzada Atif Naveed[3], Atia ur Rehman[4], Ali Hamza[1], Malaika Asghar Khan[1], Anas Jahangir[5], Madiha Iram[6]

[1]**Department of Pharmaceutical Sciences,** Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan
[2]**Research Department,** Hamdard University, Karachi, Pakistan
[3]**Department of Computer Science,** Rashid Latif Khan University, Lahore, Pakistan
[4]**Faculty of Allied Health Sciences,** Rashid Latif Khan University, Lahore, Pakistan
[5]**Department of Operation Theater Technology,** Rashid Latif Khan University, Lahore, Pakistan
[6]**Department of Zoology,** Wildlife and Fisheries, Agriculture University Faisalabad, Pakistan

***Correspondence author:** Muhammad Akhlaq. E. mail: Muhammadakhlaq377@gmail.com

Abstract

Artificial Intelligence (AI) has emerged as a transformative force in oncology, enabling the integration of genomic and multi-omic data for truly personalized cancer care. Conventional cancer management often relied on generalized treatment protocols that overlooked genetic and phenotypic diversity among patients. Advances in machine learning (ML) and deep learning (DL) now allow AI systems to analyze high-dimensional datasets including genomics, transcriptomics, proteomics, imaging, and clinical variables thus guiding tailored therapies with improved precision and reduced toxicity.

Next-Generation Sequencing (NGS) provides detailed tumor mutation profiles, while AI-driven feature selection and data fusion enhance biomarker discovery, risk stratification, and therapy adaptation. Applications span the cancer care continuum: AI-powered diagnostics improve tumor detection, predictive models anticipate resistance, and Clinical Decision Support Systems (CDSS) assist oncologists with real-time, evidence-based decisions. Additionally, AI accelerates drug discovery, virtual screening, and nanomedicine design, offering efficient and targeted treatment options. Case studies in lung, breast, and rare cancers demonstrate significant improvements in diagnosis, therapy selection, and survival outcomes.

Nonetheless, challenges persist, including data privacy, algorithm transparency, infrastructure needs, and regulatory gaps. Ethical issues such as algorithmic bias and equitable access require urgent attention. Future directions emphasize reinforcement learning, causal inference, and multimodal integration to refine adaptive therapies. Ultimately, AI-driven genomic oncology marks a paradigm shift toward predictive, precise, and equitable cancer treatment, improving both survival and quality of life.

Keywords: *Artificial intelligence, Clinical decision support systems, Genomics, Machine learning, Precision oncology, Targeted therapy*

INTRODUCTION TO AI IN PERSONALIZED CANCER TREATMENT

EVOLUTION OF AI IN ONCOLOGY

Artificial Intelligence (AI) has undergone a remarkable evolution in oncology, transitioning from experimental applications to a fundamental component of cancer care. Historically, cancer treatment approached management with standardized protocols often lacking individualized nuance, which occasionally resulted in suboptimal outcomes. Early applications of AI in oncology primarily focused on image analysis and pattern recognition, facilitating improved detection of tumors and aiding radiological interpretations. Over time, technological advancements in computational power and algorithm sophistication have propelled AI into more complex domains such as treatment planning, prognosis prediction, and personalized therapy development. Contemporary AI-driven models incorporate vast, heterogeneous datasets encompassing genomics, clinical variables, and imaging, thereby revolutionizing decision-making processes in oncology. This paradigm shift aligns with the broader movement toward personalized medicine, aiming to transcend traditional "one-size-fits-all" approaches by enabling patient-specific interventions grounded in molecular and clinical realities, substantially improving outcomes and reducing unnecessary toxicities (1).

The transition from standard cancer care toward AI-augmented personalized medicine is a pivotal milestone in oncology. Previously, the variability among patients' genetic and phenotypic profiles was often overlooked, with treatments designed under population averages. AI disrupts this paradigm by leveraging machine learning (ML) and deep learning (DL) techniques to analyze multi-omic and clinical data, generating tailored therapeutic plans informed by each patient's unique attributes. This approach enhances the precision of cancer therapies and allows real-time adaptation based on dynamic patient responses. AI's capacity to assimilate complex data sources and predict nuanced treatment efficacy supports a shift towards actionable, individualized clinical decision-making, encompassing drug selection, dosing regimens, and timing strategies (2).

AI's transformative role spans the entire oncologic treatment continuum, from diagnostics to survivorship. In diagnostics, AI algorithms enhance accuracy and speed in tumor identification through sophisticated image analysis and pattern recognition. For treatment optimization, AI models predict response rates, identify potential resistance mechanisms, and suggest combination therapies. Equally, AI assists with monitoring treatment efficacy and adjusting interventions dynamically based on evolving disease characteristics and patient health status. Collectively, these innovations herald a future of oncology where treatment decisions are more predictive, adaptive, and empathetic to patient-specific factors, underscoring the potential of AI to improve survival rates and quality of life for cancer patients globally (3).

IMPORTANCE OF PERSONALIZED MEDICINE IN CANCER THERAPY

Personalized medicine, particularly within oncology, refers to the strategic customization of therapeutic approaches tailored to the molecular and phenotypic profile of individual patients or specific patient subgroups. Known as precision oncology, this approach harnesses extensive genetic, transcriptomic, proteomic, and other omics data to classify tumor subtypes, identify actionable mutations, and select targeted treatments that maximize benefit while minimizing adverse effects. The scope extends beyond individualized treatments, incorporating population-level stratification to optimize care delivery while addressing heterogeneity within and across tumors (4).

Tumor heterogeneity remains one of the foremost challenges in effective cancer therapy. Variations among cancer cells within the same tumor (intratumoral heterogeneity) and across patients with ostensibly similar diagnoses (intertumoral heterogeneity) complicate treatment responses and contribute to therapeutic resistance. Understanding the molecular and biological diversity underlying this heterogeneity is crucial for prognostication and for devising effective, personalized therapeutic regimens. AI-driven methodologies aid in deciphering these complex biological patterns by integrating multi-modal datasets to subgroup patients based on predictive biomarkers, facilitating more accurate risk stratification and tailored interventions (5).

Tailored treatments offer distinct advantages over conventional therapeutic strategies reliant on generalized protocols. Personalized medicine enhances therapeutic efficacy by ensuring that selected interventions target molecular drivers relevant to the patient's cancer biology. This precision reduces unnecessary exposure to ineffective treatments, thereby decreasing toxicities and improving patients' quality of life. Additionally, personalization fosters cost-effective care by focusing resources on therapy options with higher likelihoods of success, which may ultimately reduce the burden on healthcare systems. AI augments these benefits by refining predictive accuracy for treatment response and resistance, thereby enabling dynamic treatment adaptation according to evolving clinical data (6).

INTEGRATION OF MULTI-OMICS AND GENOMIC DATA

Genomic data, along with transcriptomics, proteomics, and metabolomics, collectively termed multi-omics, play a central role in advancing precision oncology. These diverse biological data modalities provide comprehensive insights into tumor biology and patient-specific molecular landscapes. The complexity and sheer volume of multi-omic datasets necessitate robust computational infrastructures and innovative analytical methodologies to translate data into clinically actionable knowledge. AI technologies, with their proficiency in pattern recognition and data integration, are uniquely positioned to facilitate this translation by unraveling intricate biological interactions and correlating them with clinical outcomes (7).

Integrating multi-omics data into clinical decision-making presents significant challenges. Diverse data formats, varying scales, and disparate sources can impede effective aggregation and interpretation. Additionally, the lack of standardized data acquisition protocols and differences in cohort characteristics introduce heterogeneity that complicates analyses. Addressing these issues requires sophisticated bioinformatics pipelines and standardized clinical informatics frameworks that facilitate harmonization and quality control. Despite challenges, AI-driven solutions have begun to effectively synthesize multi-omics alongside clinical information, enabling precision oncology to move closer to routine clinical practice (8).

AI models demonstrate superior capability to handle these high-dimensional omics datasets through advanced machine learning and deep learning algorithms. These models learn latent representations and complex relationships within multi-omic data, discerning salient biomarkers predictive of treatment response, prognosis, and adverse events. By integrating multi-omics with longitudinal clinical data, AI facilitates dynamic risk assessment and personalized therapy optimization. Furthermore, AI enhances biomarker discovery and validation, ultimately guiding therapeutic decisions and accelerating precision oncology's clinical uptake (9).

GENOMIC DATA ACQUISITION AND ANALYSIS TECHNIQUES

NEXT-GENERATION SEQUENCING (NGS) IN CANCER GENOMICS

Next-Generation Sequencing (NGS) technologies have revolutionized cancer genomics by enabling large-scale, rapid, and cost-effective analysis of genomic alterations. NGS systematically sequences DNA and RNA, allowing comprehensive profiling of somatic mutations, copy number variations, gene fusions, and transcriptomic alterations. These capabilities enable detailed molecular characterizations of tumors, aiding in identifying driver mutations, resistance mechanisms, and therapeutic targets. NGS platforms underpin the generation of personalized oncologic profiles, foundational to precision treatment strategies (10).

Applications of NGS extend beyond detecting somatic mutations to include germline variant analyses that provide insights into inherited cancer risk factors, facilitating preventive strategies and familial counseling. The comprehensive mutation landscapes generated by NGS inform clinical decision-making, including eligibility for targeted therapies and immunotherapies. Moreover, longitudinal NGS analyses monitor clonal evolution and resistance development, allowing adaptive therapeutic adjustments, crucial in managing advanced malignancies (11).

Nevertheless, NGS presents challenges concerning data volume and complexity. The enormous datasets generated require substantial computational resources for alignment, variant calling, annotation, and interpretation. Interpreting the clinical significance of variants, especially variants of unknown significance (VUS), remains a bottleneck. Additionally, the heterogeneity of sequencing platforms and bioinformatics pipelines can impact consistency and reproducibility of genomic results. Integrating NGS data into clinical workflows demands robust quality control, standardization, and comprehensive interpretation frameworks supported by AI methodologies designed to augment analytical throughput and accuracy (12).

DATA PROCESSING AND FEATURE SELECTION WITH AI

Effective processing of genomic data hinges on extracting meaningful features predictive of clinical outcomes, which is often hindered by high dimensionality and noise inherent in omics datasets. Feature selection techniques serve to identify relevant biomarkers or genomic features while reducing dimensionality to improve model performance and interpretability. Multiple strategies including filter, wrapper, and embedded methods have been applied, each with differential trade-offs between computational efficiency and model specificity (5).

Deep learning approaches offer an advanced avenue for biomarker discovery through automatic hierarchical feature extraction from raw genomic data. These models, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), reveal complex nonlinear relationships and high-level abstractions, enabling the identification of genomic alterations associated with treatment resistance or sensitivity. The adaptability of deep learning to diverse data types and scales enhances its applicability in translational oncology research (12).

Overfitting and model interpretability remain salient challenges in high-dimensional genomic data analysis. AI applications employ regularization techniques, cross-validation, and synthetic data augmentation to mitigate overfitting risks. Interpretability is enhanced through methods such as SHapley Additive exPlanations (SHAP) and Local Interpretable Model-agnostic Explanations (LIME), which provide transparency regarding feature contributions, fostering clinical trust and facilitating actionable insights. These methodological advancements are critical to translating AI-driven genomic analyses into reliable clinical tools (13).

INTEGRATIVE OMICS AND AI-DRIVEN DATA FUSION

The power of AI is markedly demonstrated in multi-modal data fusion, integrating various omics layers—including genomics, transcriptomics, proteomics—and clinical data to generate holistic models of cancer biology. These integrative frameworks leverage machine learning techniques to align and process heterogeneous data, capturing interdependencies that single-omic analyses might overlook. Such fusion approaches enhance prognostic accuracy and enable precise therapeutic stratification (14).

Multi-source data integration frameworks facilitate the dynamic incorporation of evolving patient data, allowing real-time updates of risk profiles and therapeutic recommendations. Ensemble modeling techniques combining random forests, gradient boosting, and deep neural networks have been applied to balance predictive robustness and computational scalability. These models are often embedded within clinical decision support systems, facilitating the translation of complex integrative analyses into user-friendly interfaces for oncologists (15).

Cross-attention transformer models represent a cutting-edge advancement in multimodal AI integration. These architectures employ attention mechanisms to prioritize salient features across varied data modalities, effectively learning contextual relationships and synergistic effects that impact survival and therapeutic responsiveness. Early evidence demonstrates that such models outperform traditional unimodal predictors, offering interpretable visualizations that elucidate underlying biological mechanisms critical in personalized oncology (14).

AI MODELS FOR TARGETED THERAPY RECOMMENDATIONS

MACHINE LEARNING ALGORITHMS IN TREATMENT DECISION-MAKING

Machine learning algorithms are fundamental in predicting optimal treatment regimens by analyzing patient-specific genomic and clinical data. Methods such as Random Forests and Support Vector Machines provide robust classification capabilities, offering interpretable models that identify treatment-responsive subgroups. Convolutional and recurrent neural networks extend these capabilities by capturing complex temporal and spatial patterns, enriching prediction accuracy for therapy efficacy and resistance development (2).

Deep learning techniques have been particularly effective in identifying drug resistance markers by uncovering intricate genomic and epigenomic signatures associated with therapeutic failure. These models facilitate the early prediction of resistance, enabling clinicians to adjust treatment strategies proactively. Integration with phenotypic patient data further refines these predictions, allowing the development of adaptive therapy plans responsive to emerging clinical dynamics (4).

Robust model validation is critical to ensure clinical utility of AI predictions. Cross-validation methodologies, independent test cohorts, and prospective validation studies are employed to assess predictive accuracy and generalizability. Metrics such as area under the receiver operating characteristic curve (AUC), precision-recall curves, and calibration plots are standard in evaluating performance, guiding iterative improvement in AI therapy recommendation systems (15).

AI IN IDENTIFYING ACTIONABLE GENOMIC ALTERATIONS

A key contribution of AI to precision oncology lies in the interpretation of complex genomic mutation data to identify clinically actionable alterations. AI-based mutation interpretation platforms assimilate variant annotation, literature evidence, and drug databases to generate therapeutic recommendations. Comparative analyses reveal significant variability across different computational tools, highlighting the need for standardization and consensus building in mutation-driven treatment guidance (16).

Standardizing genomic data annotation remains challenging due to heterogeneous data sources, variable nomenclature, and continuously evolving biological knowledge. AI methods contribute to harmonization by employing natural language processing and knowledge graph techniques to reconcile disparate terminologies and contextual literature, enhancing the consistency and reliability of mutation annotation (17).

Beyond annotation, AI algorithms actively identify novel therapeutic targets by analyzing large-scale genomics and proteomics datasets to detect biomarkers and driver mutations unrecognized by traditional methods. These capabilities support drug repurposing strategies and the development of personalized immunotherapies, expanding the repertoire of effective targeted treatments (18).

AI FOR DRUG DISCOVERY AND DESIGN

AI accelerates targeted drug discovery by simulating molecular interactions, predicting drug-target affinities, and optimizing candidate compounds in silico, reducing dependence on protracted experimental cycles. Machine learning models enable virtual screening of vast chemical libraries to prioritize molecules with desirable pharmacodynamic and pharmacokinetic profiles, enhancing the efficiency of drug development pipelines (3).

Nanotechnology convergence with AI further transforms drug delivery systems. AI-optimized nanoformulations enhance encapsulation efficiency, control release kinetics, and improve site-specific delivery, addressing pharmacological challenges such as bioavailability and off-target toxicity. These advancements potentiate the development of personalized drug delivery strategies tailored to individual tumor biology and patient physiology (19).

Bioinformatics approaches complement AI methods by facilitating the screening and identification of central protein targets within complex biological networks. Integration of network pharmacology with AI models enables the rational design of multi-target drugs and combinatorial therapies, aiming to circumvent resistance mechanisms and enhance therapeutic efficacy (20).

CLINICAL IMPLEMENTATION OF GENOMIC AI TOOLS

AI-POWERED CLINICAL DECISION SUPPORT SYSTEMS (CDSS)

AI-driven Clinical Decision Support Systems (CDSS) integrate real-time clinical, genomic, and imaging data to assist clinicians in making personalized cancer treatment decisions. These systems leverage predictive models to evaluate treatment options, simulate outcomes, and optimize therapy selection based on patient-specific biomarkers and clinical parameters. Such tools enhance precision, reduce cognitive burden, and promote evidence-based oncology practice (6).

Integration of electronic health records (EHRs) with genomic platforms within AI-CDSS facilitates seamless data flow, enabling comprehensive patient assessments. Real-time analytics support adaptive treatment planning by continuously incorporating new laboratory results, imaging findings, and patient-reported outcomes. This end-to-end data integration strengthens clinical decision-making and adherence to therapy guidelines (21).

Clinical application of AI-CDSS has demonstrated positive impacts on treatment optimization and patient adherence. By providing transparent, evidence-backed recommendations and alerts regarding drug interactions or side effects, these systems improve safety and efficacy, fostering better clinical outcomes and enhanced patient monitoring over the course of therapy (22).

AI IN TUMOR BOARDS AND MULTIDISCIPLINARY CARE

Tumor boards constitute the cornerstone of multidisciplinary cancer care, where collaboration among oncologists, pathologists, radiologists, and other specialists occurs to develop consensus treatment plans. Incorporation of AI insights and data science expertise enriches tumor board deliberations by providing comprehensive analyses of genomic and clinical datasets, facilitating personalized care decisions informed by robust evidence (21).

Collaborative models that embed AI analytics into tumor board workflows improve treatment guidance by highlighting molecular targets, predicting therapeutic responses, and identifying clinical trial eligibility. This integration promotes precision oncology even in complex cases, ensuring tailored interventions that reflect the most current scientific knowledge and patient-specific variables (1).

Numerous case studies illustrate improved patient outcomes resulting from AI-supported tumor boards. For example, multimodal AI models synthesizing radiomics and genomics inform more accurate staging and therapy choices in lung cancer. These improvements translate into increased survival rates and reduced treatment-associated morbidity, validating the practical benefits of AI-augmented multidisciplinary approaches (23).

CHALLENGES AND BARRIERS TO CLINICAL INTEGRATION

Despite the promise of AI in personalized oncology, several challenges hinder widespread clinical adoption. Data privacy concerns arise due to the sensitive nature of genomic and health information, necessitating stringent safeguards to prevent unauthorized access and maintain patient confidentiality. Algorithm transparency is equally critical to engender clinician and patient trust, demanding explainable AI methodologies that clarify decision pathways (18).

Infrastructure limitations, especially in resource-constrained settings, represent substantial barriers. The computational demands of AI tools, coupled with the need for integrated health informatics systems, require significant investments in technology and personnel. These hurdles disproportionately affect low- and middle-income countries, exacerbating global disparities in cancer care (21).

Successful implementation also depends on clinician training and acceptance. Oncologists and allied health professionals need education on AI functionalities, data interpretation, and integration into patient management protocols. Moreover, regulatory frameworks lag behind technological advances, creating uncertainty about standards for validation, approval, and oversight of AI-driven clinical tools (24).

CASE STUDIES IN AI-DRIVEN PRECISION ONCOLOGY

NON-SMALL CELL LUNG CANCER (NSCLC)

NSCLC represents a major focus area for AI integration given its prevalence and molecular complexity. AI models have effectively predicted immune response profiles, optimizing immunotherapy regimens and minimizing adverse effects. By analyzing multi-omic profiles, AI helps stratify patients likely to benefit from checkpoint inhibitors or targeted therapies, thereby personalizing treatment plans (25).
Integration of radiomics with genomic data enhances NSCLC treatment by providing non-invasive biomarker assessment, enabling dynamic monitoring of tumor evolution and response. AI algorithms applied to imaging data identify phenotypic patterns correlating with genotypic alterations, supporting precision staging and therapeutic decision-making (23).

However, challenges remain in biomarker validation and dealing with treatment resistance. AI aids in longitudinal data analyses to identify emergent resistance mechanisms, yet heterogeneous data quality and limited prospective validation studies constrain translation. Addressing these limitations is critical for realizing AI's full potential in NSCLC management (26).

BREAST CANCER

In breast cancer, AI facilitates enhanced diagnosis and personalized therapy by analyzing imaging, pathology, and genomic data. Machine learning models classify tumor subtypes, predict recurrence risk, and stratify patients accurately, thereby guiding treatment choices ranging from surgery to systemic therapies. These approaches improve survival outcomes and reduce overtreatment (19).

Advanced tumor classification through AI leverages large datasets for pattern recognition within histopathology and molecular profiles. These models support risk stratification, allowing clinicians to tailor adjuvant therapy intensity according to individual prognostic factors, contributing to optimized treatment regimens (13).

AI-optimized nanoparticles and nanomedicine further refine breast cancer care by improving targeted drug delivery. These AI-designed nanoformulations address challenges related to drug solubility, release kinetics, and site-specificity, offering solutions that enhance therapeutic indices while minimizing systemic toxicity (20).

RARE AND AGGRESSIVE CANCERS: MEDULLARY THYROID CARCINOMA (MTC)

Medullary Thyroid Carcinoma (MTC), a rare and aggressive malignancy, exemplifies the complexities of personalized oncology. The integration of holomics and AI enables comprehensive analyses encompassing biochemical, radiological, histological, and genomic data to tackle MTC's heterogeneous nature. This multifaceted approach improves diagnostic accuracy and informs individualized treatment strategies, crucial given the disease's poor prognosis (7).

AI facilitates decision-making by synthesizing diverse datasets and integrating clinical expertise, supporting global collaboration and data sharing. These efforts promote equitable access to personalized care by overcoming geographic and economic barriers, aligning with broader health equity goals (7).

AI-BASED BIOMARKERS AND PREDICTIVE MODELS

DEVELOPMENT OF AI-DRIVEN BIOMARKERS

AI accelerates the identification of imaging and molecular biomarkers, enhancing precision oncology by enabling early diagnosis, prognostic stratification, and monitoring therapeutic responses. Machine learning models analyze digital pathology images to quantify biomarker expressions such as HER2 and Ki67, offering objective and reproducible assessments beyond human observer limitations (27).

Predictive modeling based on AI integrates multi-modal data to forecast treatment outcomes and patient survival. These models incorporate variables from clinical history, genetic profiles, and imaging findings to generate personalized prognostic indices that inform therapeutic choices (14).

Liquid biopsy biomarkers benefit from AI-enhanced analytics, enabling non-invasive detection of circulating tumor DNA and minimal residual disease with high sensitivity. This real-time biomarker monitoring supports early intervention and treatment adaptations, improving management of residual or recurrent cancer (28).

RADIOMICS AND PATHOMICS INTEGRATION

Radiomics involves extracting quantitative imaging features that correlate with tumor biology, while pathomics analyzes histopathological images through AI algorithms. Integrating these fields links phenotypic imaging data with underlying genotypes, creating a comprehensive tumor characterization that enhances diagnostic precision and therapy selection (29).

Automated pathology feature extraction increases reproducibility and reduces inter-observer variability, addressing one of the main limitations of manual pathology assessments. AI-driven analyses enable the detection of subtle morphological patterns that might escape human observation, thereby refining tumor subtype classification and improving prognostication (27).

These integrated technologies contribute substantially to personalized medicine by facilitating precise risk stratification and supporting more precise targeting in therapeutic interventions, including radiotherapy and systemic treatments (30).

LIMITATIONS AND VALIDATION OF AI BIOMARKERS

Despite promising advances, challenges persist in standardizing AI-generated biomarkers across institutions and populations. Variations in imaging acquisition protocols, data annotation, and algorithmic methodologies hinder reproducibility and large-scale validation. Rigorous clinical trials and multi-site collaborations are necessary to establish robustness and generalizability of these biomarkers (17).

Regulatory pathways for clinical adoption are still evolving. Ensuring compliance with safety, efficacy, and quality standards requires transparent AI models with validated clinical utility. Navigating these frameworks remains complex, necessitating ongoing dialogue between technologists, clinicians, and regulatory bodies (24).

Ethical considerations around bias in training datasets, algorithmic fairness, and patient consent warrant proactive strategies to mitigate disparities and ensure equitable biomarker deployment. These include diverse dataset curation, algorithm auditing, and transparent reporting to build trust within clinical and patient communities (31).

ETHICAL, REGULATORY, AND DATA PRIVACY CONSIDERATIONS

ETHICAL CHALLENGES IN AI-DRIVEN ONCOLOGY

The deployment of AI in oncology raises significant ethical concerns, especially related to algorithmic bias that may exacerbate disparities in treatment recommendations and outcomes. Ensuring fairness requires deliberate efforts to include diverse populations in model training and validation, mitigating skewed predictions based on socioeconomic, racial, or ethnic factors (22).

Patient consent and data sovereignty are critical given the sensitive nature of genomic data. Patients must be fully informed about how their data are used, stored, and shared, with mechanisms to control access and revoke permissions. Ethical frameworks must prioritize autonomy, confidentiality, and transparency to maintain patient trust (10).

Transparency and explainability of AI models are essential to ethical integration. Clinicians need to understand AI decision rationales to provide informed recommendations, and patients deserve clear explanations regarding AI-guided care. Techniques for interpretable AI enhance accountability and facilitate shared decision-making (18).

REGULATORY FRAMEWORKS FOR AI IN PRECISION MEDICINE

Current regulatory guidelines for AI tools in oncology remain fragmented. While some AI-based diagnostics have received approvals, regulatory bodies continue to grapple with the novel challenges posed by adaptive algorithms, data dependencies, and opaque decision-making processes. There is a pressing need for comprehensive frameworks that address validation, monitoring, and updating of AI tools (24).

Challenges in regulation include establishing standards for data quality, interoperability, and clinical validation. Balancing innovation with patient safety requires consistent evaluation of AI performance, risk assessment, and post-market surveillance. Multistakeholder engagement is necessary to harmonize standards and accelerate responsible AI adoption globally (17).

Future directions focus on developing harmonized AI regulatory frameworks that promote transparency, cross-jurisdictional acceptance, and ongoing compliance. International collaborations may facilitate these efforts, ensuring that patients worldwide benefit equitably from AI advancements (8).

ENSURING DATA SECURITY AND PRIVACY

Securing genomic and health data demands robust encryption, anonymization, and access control measures embedded within AI platforms. Such technical safeguards prevent unauthorized data breaches and uphold stringent privacy standards essential for patient confidentiality (24).

Balancing data sharing and confidentiality is vital to enable collaborative research and AI model improvement without compromising individual privacy. Techniques such as federated learning and secure multiparty computation offer promising solutions that allow decentralized data utilization while safeguarding personal information (32).

Compliance with data protection regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union is mandatory. These frameworks guide the ethical collection, storage, and usage of health data, ensuring patient rights are respected in AI applications (24).

FUTURE DIRECTIONS IN AI AND GENOMIC INTEGRATION

ADVANCES IN AI METHODOLOGIES FOR CANCER TREATMENT

Emerging AI methodologies, including large-scale transformer architectures and foundation models, offer unprecedented capabilities in integrating complex multimodal data for cancer treatment. These models enhance contextual understanding and prediction accuracy, opening new frontiers for personalized oncology (23).

Incorporation of reinforcement learning and causal inference represents promising avenues for dynamic treatment optimization. These AI methods learn adaptive strategies that modify therapeutic interventions in response to patient feedback and changing tumor biology, facilitating precision dosing and combination therapy design (21).

Ongoing improvements in model interpretability and clinical utility aim to bridge the gap between AI advancements and practical application. Interdisciplinary collaborations among AI developers, clinicians, and bioinformaticians are crucial to translate methodological innovations into effective patient-centric tools (33).

EXPANDING MULTI-MODAL DATA AND REAL-TIME ANALYTICS

The integration of wearable device outputs, environmental exposures, and lifestyle information with genomic data heralds a new era of comprehensive patient monitoring and management. AI models capable of synthesizing these diverse data streams hold potential for early risk detection and preventive interventions (22).

Development of dynamic, adaptive treatment models, facilitated by continuous data flows and AI feedback loops, enables real-time personalization of cancer therapies. Such frameworks accommodate temporal changes in patient condition, therapeutic response, and tumor evolution, moving cancer care toward a more proactive paradigm (15).

These continuous monitoring systems support precision oncology by predicting imminent disease progression, treatment toxicities, and relapse, allowing timely clinical responses that improve outcomes and reduce unnecessary interventions (2).

PROMOTING EQUITY AND GLOBAL ACCESSIBILITY

Addressing inequities in AI-driven precision oncology requires tailored strategies targeting infrastructural, economic, and educational barriers in resource-limited settings. Efforts to adapt AI tools for low- and middle-income countries promote more inclusive cancer care (21).

Telemedicine, mobile health (mHealth), and AI-enabled remote diagnostics expand access to specialized oncology services, especially in underserved regions. These technologies facilitate patient monitoring, treatment adherence, and education, bridging gaps induced by geographic and socioeconomic factors (24).

Global collaborative networks leveraging AI analytics enhance data sharing, clinical trials participation, and capacity building. Such alliances foster equitable distribution of AI benefits and accelerate translation into practice worldwide (7).

CRITICAL EVALUATION OF CURRENT AI IMPLEMENTATIONS

STRENGTHS OF AI INTEGRATION IN ONCOLOGY

The integration of AI in oncology significantly enhances diagnostic accuracy by leveraging complex pattern recognition to detect malignancies earlier and more precisely than traditional methods. This improved accuracy directly informs personalized treatment planning, tailoring therapies that maximize efficacy for individual patients (3).

AI implementations demonstrate tangible improvements in patient outcomes, including increased survival rates and reduced toxicity. Models predicting treatment response and adverse events enable clinicians to optimally balance therapeutic benefits and risks (1).

Moreover, AI optimizes therapeutic regimens, allowing dynamic adjustments and combination strategies that mitigate resistance development and improve management of complex tumor biology, thereby improving quality of life (33).

LIMITATIONS AND CHALLENGES

AI in oncology faces challenges related to data heterogeneity, which can impact model performance due to variability in patient populations, sequencing platforms, and clinical practices. Overfitting remains a technical risk that could limit generalizability of AI models outside training datasets (12).

The scarcity of large, annotated datasets further constrains model training and validation, requiring concerted efforts to curate high-quality, representative data resources. This limitation is particularly acute for rare cancers and minority populations (34).

Resistance to adoption persists among clinicians and patients due to concerns over transparency, trustworthiness, and potential disruptions to existing workflows, underscoring the need for comprehensive education and demonstration of clinical benefits (31).

IDENTIFIED RESEARCH GAPS AND OPPORTUNITIES

Longitudinal studies assessing real-world impacts of AI-driven interventions remain limited but are essential to evaluate sustained efficacy and safety, informing clinical practice guidelines and policy development (22).

Research exploring AI applications in rare cancers and highly heterogeneous tumor types offers opportunities to address unmet clinical needs with precision medicine approaches informed by AI's pattern recognition capabilities (7).

Enhanced collaboration between clinicians, data scientists, and regulatory authorities is needed to co-develop clinically relevant, validated AI tools that are scalable and patient-centered, facilitating accelerated integration into oncology care (21).

CONCLUSION AND RECOMMENDATIONS

Evidence demonstrates that AI markedly enhances targeted therapy decisions by integrating vast genomic and clinical data, enabling precision oncology paradigms that improve patient outcomes. The critical role of genomics integration within AI frameworks is evident in advancing individualized treatment planning and adaptive therapeutic strategies (25).

Genomic integration fosters a deeper understanding of tumor biology, driving personalized regimens that improve efficacy and reduce toxicity. AI's capacity to synthesize complex datasets transforms oncology from reactive to predictive and preventive medicine, yielding broad clinical implications and tangible patient benefits (4).

RECOMMENDATIONS FOR CLINICAL PRACTICE

Clinics should prioritize adoption of validated AI tools within multidisciplinary teams to harness comprehensive data analysis capabilities, promoting evidence-based and personalized cancer care (21).
Clinician training programs focusing on AI functionalities, genomic data interpretation, and ethical considerations are imperative to optimize utilization and trust in AI-augmented decision-making

processes (24). Development and implementation of standardized workflows and quality control measures are necessary to ensure consistency, accuracy, and safety in AI-driven oncology applications (16).

FUTURE RESEARCH AND POLICY DIRECTIONS

Investment in infrastructure that supports high-throughput data processing, secure data management, and user-friendly AI interfaces will catalyze broader implementation of precision oncology solutions (24).

Policy efforts should encourage transparent AI development, rigorous clinical assessment, and open data sharing, fostering innovation while safeguarding patient safety and privacy (17).

Maintaining focus on equitable access and ethical frameworks will ensure AI's benefits are distributed fairly, addressing disparities and enabling global advances in personalized cancer care (8).

Conflict of interest:

There is no conflict of interest among authors.

Declaration of generative AI and AI-assisted technologies in the writing process:

During the preparation of this work the author(s) used Chat GPT to enhance the readability of the article. After using this tool/service, the author(s) reviewed and edited the content as needed and took(s) full responsibility for the content of the publication.

Authors' contribution:

AM conceived the idea and designed the outline of the review; ZK and HT conducted the literature search and collected relevant studies; AM and FR analyzed and organized the information; ZK drafted the initial manuscript; HT and FR critically revised it for important intellectual content. All authors reviewed and approved the final version of the manuscript before submission.

References:

1. Sherani AMK, Khan M, Qayyum MU, Hussain HK. Synergizing AI and Healthcare: Pioneering Advances in Cancer Medicine for Personalized Treatment. Int J Multidiscip Sci Arts. 2024;3(1):3562.
2. Vegesna V. AI-Driven Personalized Medicine: A Framework for Tailored Cancer Treatment. Int J Innov Res Appl Eng. 2024;1106(06):?
3. Hossain MF, Uddin MM. AI in Precision Oncology: Revolutionizing Cancer Treatment Through Personalized Drug Discovery. J Comput Sci Technol Stud. 2025;7(2):28.
4. Dlamini Z, Skepu A, Kim N, Mkhabele M. AI and Precision Oncology in Clinical Cancer Genomics: From Prevention to Targeted Cancer Therapies — An Outcomes Based Patient Care. IMU. 2022:100965.
5. Wang J, Zhang Z, Wang Y. Utilizing Feature Selection Techniques for AI-Driven Tumor Subtype Classification: Enhancing Precision in Cancer Diagnostics. Biomolecules. 2025;15(1):81.
6. Bongurala AR, Save D, Virmani A. Progressive Role of Artificial Intelligence in Treatment Decision-Making in the Field of Medical Oncology. Front Med. 2025:1533910.
7. Luvhengo T, Moeng M, Sishuba N, Makgoka M, Jonas L, Mamathuntsha T G, Mbambo T, Kagodora SB, Dlamini Z. Holomics and Artificial Intelligence-Driven Precision Oncology for Medullary Thyroid Carcinoma: Addressing Challenges of a Rare and Aggressive Disease. Cancers. 2024;16(203469):34-69?
8. Boini A, Grasso V, Taher H, Gumbs AA. Artificial Intelligence and the Impact of Multiomics on the Reporting of Case Reports. World J Clin Cases. 2025;13(15):101188.
9. Tanaka I, Furukawa T, Morise M. The Current Issues and Future Perspective of Artificial Intelligence for Developing New Treatment Strategy in Non-Small Cell Lung Cancer: Harmonization of Molecular Cancer Biology and Artificial Intelligence. Cancer Med Res. 2021;21(65-7).
10. Hatijar H, Auliafendri N, Surjoseto R, Sujati Ni K, Nazarudin M. Application of Genomic Technology in Early Diagnosis and Personalized Treatment for Cancer Patients. Glob Adv Res Rev. 2024;2(1):66.
11. Rabbani M, Kanevsky J, Kafi K, Chandelier F, Giles FJ. Role of Artificial Intelligence in the Care of Patients with Non-Small Cell Lung Cancer. Eur Clin Invest. 2018;48(4):e12901.
12. TofayelGonee M Md. Integrating Genomic Data and Machine Learning to Advance Precision Oncology and Targeted Cancer Therapies. Int J Med Toxicol Legal Med. 2022;25(3-4):993.
13. Reddy A. AI and Machine Learning in Breast Cancer: Advancing Precision Medicine Through Data-Driven Models. Int J Innov Eng. 2025;4(4):37.

14. Hu Y, Li X, Yi Y, Huang Y, Wang G, Wang D. Deep Learning-Driven Survival Prediction in Pan-Cancer Studies by Integrating Multimodal Histology-Genomic Data. Bioinfor Biol Insights. 2025;bbaf121.
15. Manju M, Sujataroy M, Anuratha T, Dhanasri S, Thirumalaivasan V. Integrative Personalized Oncology: Leveraging Multi-Source Data and Drug Solubility for Optimal Cancer Treatment. IEEE ISACC. 2025:10969289.
16. Patel J. Mutation Based Treatment Recommendations from Next Generation Sequencing Data: A Comparison of Web Tools. Oncotarget. 2016;7(5):8017-?.
17. Ligero M, El Nahhas OS, Aldea M, Kather JN. Artificial intelligence-based biomarkers for treatment decisions in oncology. Trends in Cancer. 2025;11(3):232-44.
18. Olawade DB, David-Olawade AC, Adereni T, Egbon E, Teke J, Boussios S. Integrating AI into Cancer Immunotherapy : A Narrative Review of Current Applications and Future Directions. Diseases. 2025;13(1):0024.
19. Singh D, Sachdeva D, Singh L. Advancing Breast Cancer Drug Delivery: The Transformative Potential of Bioinformatics and Artificial Intelligence. Current Cancer Therapy Reviews. 2025;21(3):254-64.
20. Das KP, Chandra J. Nanoparticles and Convergence of Artificial Intelligence for Targeted Drug Delivery for Cancer Therapy: Current Progress and Challenges. Front Med. Technol. 2023;4:1067144.
21. Tan MJ, Lichlyter DA, Maravilla NM, Schrock WJ, Ting FI, Choa-Go JM, Francisco KK, Byers MC, Abdul Karim H, AlDahoul N. The data scientist as a mainstay of the tumor board: global implications and opportunities for the global south. Frontiers in Digital Health. 2025;7:1535018.
22. Forkuo AY, Ikhalea N, Chianumba E C, Mustapha A Y. Reviewing the Impact of AI in Improving Patient Outcomes Through Precision Medicine. Int J Adv Multidisciplinary Res Stud. 2024;4(6):4060.
23. Zhong J, Wang Y, Zhu D, Wang Z. A Narrative Review on Large AI Models in Lung Cancer Screening, Diagnosis, and Treatment Planning. arXiv preprint arXiv:2506.07236. 2025.
24. Karimi AM, Forood O, Adegboyega D, Idoko J E, Oni O, Ajaelu C S, Idoko F A. Advancements in Health Information Technology and Their Role in Enhancing Cancer Care: Innovations in Early Detection, Treatment, and Data Privacy. GSC Adv Res Rev. 2024;21(1):0380.
25. Sabrouty RE, Elouadi A. Harnessing AI for Precision Oncology: Transformative Advances in Non-Small Cell Lung Cancer Treatment. So IC. 2024:2078.
26. Restrepo JC, Dueas D, Corredor Z, Liscano Y. Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. Cancers. 2023;15(13):3474.
27. 27. Fatima G, Alhmadi HB, Mahdi A A, Hadi N R, Fedako JN, Magomedova A, Parvez S, Raza A M. Transforming Diagnostics: A Comprehensive Review of Advances in Digital Pathology. Cureus. 2024;16(4):e71890.
28. Akhlaq M, Saqlain M, Wasif Z, Hanan A, Iddrise A, Habib T, Faiz N, Wasif A. Targeted and controlled drug delivery in cancer: a nanotechnological approach in cancer treatment: a review of recent advances. Journal of Medical & Health Sciences Review. 2025;2(2):4657-74.
29. Feretzakis G. Emerging Trends in AI and Radiomics for Bladder, Kidney, and Prostate Cancer: A Critical Review. Cancers. 2024;16(4):0810.
30. Uchikov P, Khalid U, Dedaj-Salad GH, Ghale D, Rajadurai H, Kraeva M, Kraev K, Hristov B, Doykov M, Mitova V, Bozhkova M. Artificial intelligence in breast cancer diagnosis and treatment: advances in imaging, pathology, and personalized care. Life. 2024 Nov 8;14(11):1451.
31. Ahmad Z, Rahim S, Zubair M, Abdul-Ghafar J. Artificial intelligence (AI) in medicine, current applications and future role with special emphasis on its potential and promise in pathology: present and future impact, obstacles including costs and acceptance among pathologists, practical and philosophical considerations. A comprehensive review. Diagnostic pathology. 2021;16(1):24.
32. Fashoyin-Aje L, Sanghavi K, Bjornard K, Bodurtha J. Integrating genetic and genomic information into effective cancer care in diverse populations. Annals of oncology. 2013;24:vii48-54.
33. Akter S. AI-driven precision medicine: transforming personalized cancer treatment. Journal of AI-Powered Medical Innovations. 2024;2(1):10-21.
34. Jha S, Singh N, Ansari MA. AI-Based Cancer Risk Assessment Models: Current Trends Overview. In2025 International Conference on Cognitive Computing in Engineering, Communications, Sciences and Biomedical Health Informatics (IC3ECSBHI) IEEE. 2025:1-8.